GPhA comes out tentatively in favor of risk-based FDA inspections; Lannett gets plant with Kremers buy;

> The Generic Pharmaceutical Association says it supports the FDA's plan to create quality metrics for companies and to do risk-based inspections but suggests the agency needs to phase them in to avoid drug shortages. Release

> Mundipharma is building a manufacturing plant in Singapore. Report

> Lannett has picked up a 300,000-square-foot manufacturing facility in Seymour, IN, as part of its $1.23 billion acquisition of Kremers Urban Pharmaceuticals, the specialty generic pharmaceuticals subsidiary of UCB. Release

> Packaging company Clariant will build a new plant in India to make pharma packaging. Report

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.